{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:17:40Z","timestamp":1793729860091,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,2]]},"DOI":"10.7759\/cureus.29837","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:40:08Z","timestamp":1664790008000},"source":"Crossref","is-referenced-by-count":9,"title":["A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants"],"prefix":"10.7759","author":[{"given":"Lokesh","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miana","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Ajmera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabal","family":"Chaurasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014279117","article-title":"Initial economic damage from the COVID-19 pandemic in the United States is more widespread across ages and geographies than initial mortality impacts","volume":"117","author":"Polyakova M","year":"2020","unstructured":"Polyakova M, Kocks G, Udalova V, Finkelstein A. Initial economic damage from the COVID-19 pandemic in the United States is more widespread across ages and geographies than initial mortality impacts. Proc Natl Acad Sci U S A. 2020, 117:27934-9. 10.1073\/pnas.2014279117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013665.pub3","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19","volume":"5","author":"Struyf T","year":"2022","unstructured":"Struyf T, Deeks JJ, Dinnes J, et al.. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022, 5:CD013665. 10.1002\/14651858.CD013665.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10030393","article-title":"COVID-19 vaccine effectiveness: a review of the first 6 months of COVID-19 vaccine availability (1 January-30 June 2021)","volume":"10","author":"Hatcher SM","year":"2022","unstructured":"Hatcher SM, Endres-Dighe SM, Angulo FJ, et al.. COVID-19 vaccine effectiveness: a review of the first 6 months of COVID-19 vaccine availability (1 January-30 June 2021). Vaccines (Basel). 2022, 10:10.3390\/vaccines10030393","journal-title":"Vaccines (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer F","year":"2020","unstructured":"Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020, 586:516-27. 10.1038\/s41586-020-2798-3","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson MG","year":"2021","unstructured":"Thompson MG, Stenehjem E, Grannis S, et al.. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021, 385:1355-71. 10.1056\/NEJMoa2110362","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas EJ","year":"2021","unstructured":"Haas EJ, Angulo FJ, McLaughlin JM, et al.. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021, 397:1819-29. 10.1016\/S0140-6736(21)00947-8","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.1.68","article-title":"A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease","volume":"169","author":"Edwards KM","year":"1994","unstructured":"Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994, 169:68-76. 10.1093\/infdis\/169.1.68","journal-title":"J Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061850","article-title":"Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines","volume":"355","author":"Ohmit SE","year":"2006","unstructured":"Ohmit SE, Victor JC, Rotthoff JR, et al.. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006, 355:2513-22. 10.1056\/NEJMoa061850","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103841","article-title":"Intranasal COVID-19 vaccines: from bench to bed","volume":"76","author":"Alu A","year":"2022","unstructured":"Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine. 2022, 76:103841. 10.1016\/j.ebiom.2022.103841","journal-title":"EBioMedicine"},{"key":"ref10","unstructured":"Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. (2022). Accessed. August 19, 2022: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/comirnaty-and-pfizer-bionte...."},{"key":"ref11","unstructured":"Spikevax and Moderna COVID-19 Vaccine. (2022). Accessed. August 19, 2022: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/spikevax-and-moderna-covid-...."},{"key":"ref12","unstructured":"Novavax COVID-19 Vaccine, Adjuvanted. (2022). Accessed. August 20, 2022: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/novavax-covid-19-vaccine-ad...."},{"key":"ref13","unstructured":"Janssen COVID-19 Vaccine. (2022). Accessed. August 20, 2022: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7043e2","article-title":"COVID-19 vaccination and non-COVID-19 mortality risk - seven integrated health care organizations, United States, December 14, 2020-July 31, 2021","volume":"70","author":"Xu S","year":"2021","unstructured":"Xu S, Huang R, Sy LS, et al.. COVID-19 vaccination and non-COVID-19 mortality risk - seven integrated health care organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021, 70:1520-4. 10.15585\/mmwr.mm7043e2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref15","unstructured":"Vaccines for COVID-19. (2022). Accessed. August 19, 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/index.html."},{"key":"ref16","unstructured":"New COVID-19 Vaccine Effectiveness Data Showcase Protection Gained by 3rd and 4th Doses. (2022). Accessed. August 19, 2022: https:\/\/www.cdc.gov\/media\/releases\/2022\/s0715-COVID-VE.html."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7037e2","article-title":"Interim estimates of Covid-19 vaccine effectiveness against Covid-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - nine states, June-Augus","volume":"70","author":"Grannis SJ","year":"2021","unstructured":"Grannis SJ, Rowley EA, Ong TC, et al.. Interim estimates of Covid-19 vaccine effectiveness against Covid-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - nine states, June-Augus. MMWR Morb Mortal Wkly Rep. 2021, 70:1291-3. 10.15585\/mmwr.mm7037e2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117128","article-title":"Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina","volume":"386","author":"Lin DY","year":"2022","unstructured":"Lin DY, Gu Y, Wheeler B, et al.. Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina. N Engl J Med. 2022, 386:933-41. 10.1056\/NEJMoa2117128","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0868","article-title":"Effectiveness of Ad26.COV2.S vaccine vs BNT162b2 vaccine for COVID-19 hospitalizations","volume":"5","author":"Botton J","year":"2022","unstructured":"Botton J, Semenzato L, Jabagi MJ, Baricault B, Weill A, Dray-Spira R, Zureik M. Effectiveness of Ad26.COV2.S vaccine vs BNT162b2 vaccine for COVID-19 hospitalizations. JAMA Netw Open. 2022, 5:e220868. 10.1001\/jamanetworkopen.2022.0868","journal-title":"JAMA Netw Open"},{"key":"ref20","unstructured":"Stay Up to Date with COVID-19 Vaccines Including Boosters. (2022). Accessed. August 19, 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/stay-up-to-date.html."},{"key":"ref21","unstructured":"Interim Clinical Considerations for Use of COVID-19 Vaccines. Appendices, References, and Previous Updates. (2022). Accessed: August 19, 2022: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us-appendix.html."},{"key":"ref22","unstructured":"Allergic Reactions after COVID-19 Vaccination. (2022). Accessed. August 19, 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/allergic-reaction.html#:~:text=However%2C%20if%20you%20had%...."},{"key":"ref23","unstructured":"Possible Side Effects After Getting a COVID-19 Vaccine. (2022). Accessed. August 19, 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after.html."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson HA","year":"2006","unstructured":"Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, et al.. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006, 117:391-7. 10.1016\/j.jaci.2005.12.1303","journal-title":"J Allergy Clin Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker MS","year":"2020","unstructured":"Shaker MS, Wallace DV, Golden DB, et al.. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020, 145:1082-123. 10.1016\/j.jaci.2020.01.017","journal-title":"J Allergy Clin Immunol"},{"key":"ref26","unstructured":"COVID-19 Vaccines for People with Allergies. (2022). Accessed. August 19, 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/specific-groups\/allergies.html."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach","volume":"9","author":"Greenhawt M","year":"2021","unstructured":"Greenhawt M, Abrams EM, Shaker M, et al.. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021, 9:3546-67. 10.1016\/j.jaip.2021.06.006","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.3779","article-title":"Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose","volume":"181","author":"Krantz MS","year":"2021","unstructured":"Krantz MS, Kwah JH, Stone CA Jr, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. JAMA Intern Med. 2021, 181:1530-3. 10.1001\/jamainternmed.2021.3779","journal-title":"JAMA Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/10760296211048815","article-title":"COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis","volume":"27","author":"Hafeez MU","year":"2021","unstructured":"Hafeez MU, Ikram M, Shafiq Z, et al.. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis. Clin Appl Thromb Hemost. 2021, 27:10760296211048815. 10.1177\/10760296211048815","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref30","unstructured":"Thrombosis with Thrombocytopenia Syndrome. (2022). Accessed. August 19, 2022: https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.16496","article-title":"Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021","volume":"326","author":"Woo EJ","year":"2021","unstructured":"Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021. JAMA. 2021, 326:1606-13. 10.1001\/jama.2021.16496","journal-title":"JAMA"},{"key":"ref32","unstructured":"Guillain-Barr\u00e9 Syndrome Fact Sheet. (2022). Accessed. August 19, 2022: https:\/\/www.ninds.nih.gov\/guillain-barre-syndrome-fact-sheet."},{"key":"ref33","unstructured":"Clinical Considerations. Myocarditis After mRNA COVID-19 Vaccines. (2022). Accessed: August 19, 2022: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/myocarditis.html."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5134","article-title":"Myocarditis cases after mRNA-based COVID-19 vaccination in the US-reply","volume":"327","author":"Oster ME","year":"2022","unstructured":"Oster ME, Shay DK, Shimabukuro TT. Myocarditis cases after mRNA-based COVID-19 vaccination in the US-reply. JAMA. 2022, 327:2020-1. 10.1001\/jama.2022.5134","journal-title":"JAMA"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.47260\/jams\/1011","article-title":"Oxford-AstraZeneca COVID-19 vaccine (AZD1222), an approved, non-replicating chimpanzee adenovirus-vectored vaccine for the COVID-19 pandemic","volume":"10","author":"Guo C","year":"2021","unstructured":"Guo C. Oxford-AstraZeneca COVID-19 vaccine (AZD1222), an approved, non-replicating chimpanzee adenovirus-vectored vaccine for the COVID-19 pandemic. J Appl Med Sci. 2021, 10:1-12. 10.47260\/jams\/1011","journal-title":"J Appl Med Sci"},{"key":"ref36","unstructured":"Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 VaxzevriaTM, SII COVISHIELDTM). (2022). Accessed. September 1, 2022: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1."},{"key":"ref37","unstructured":"How the Oxford-AstraZeneca Covid-19 Vaccine Works. (2022). Accessed. September 1, 2022: https:\/\/www.nytimes.com\/interactive\/2020\/health\/oxford-astrazeneca-covid-19-vaccine.html."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin SA","year":"2022","unstructured":"Halperin SA, Ye L, MacKinnon-Cameron D, et al.. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022, 399:237-48. 10.1016\/S0140-6736(21)02753-7","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov DY","year":"2020","unstructured":"Logunov DY, Dolzhikova IV, Zubkova OV, et al.. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet. 2020, 396:887-97. 10.1016\/S0140-6736(20)31866-3","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00301-x","article-title":"Daily briefing: positive results from Sputnik V COVID vaccine trials","volume":"2","author":"Graham F","year":"2021","unstructured":"Graham F. Daily briefing: positive results from Sputnik V COVID vaccine trials. Nature. 2021, 2:10.1038\/d41586-021-00301-x","journal-title":"Nature"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi N","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, et al.. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021, 326:35-45. 10.1001\/jama.2021.8565","journal-title":"JAMA"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile","volume":"385","author":"Jara A","year":"2021","unstructured":"Jara A, Undurraga EA, Gonz\u00e1lez C, et al.. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021, 385:875-84. 10.1056\/NEJMoa2107715","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover MD","year":"2021","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, et al.. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021, 398:213-22. 10.1016\/S0140-6736(21)01429-X","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella R","year":"2021","unstructured":"Ella R, Reddy S, Blackwelder W, et al.. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021, 398:2173-84. 10.1016\/S0140-6736(21)02000-6","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin T","year":"2021","unstructured":"Momin T, Kansagra K, Patel H, et al.. Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine. 2021, 38:101020. 10.1016\/j.eclinm.2021.101020","journal-title":"EClinicalMedicine"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade A","year":"2022","unstructured":"Khobragade A, Bhate S, Ramaiah V, et al.. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022, 399:1313-21. 10.1016\/S0140-6736(22)00151-9","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068848","article-title":"Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study","volume":"375","author":"Bruxvoort KJ","year":"2021","unstructured":"Bruxvoort KJ, Sy LS, Qian L, et al.. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021, 375:e068848. 10.1136\/bmj-2021-068848","journal-title":"BMJ"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews N","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, et al.. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022, 386:1532-46. 10.1056\/NEJMoa2119451","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-022-00013-3","article-title":"Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England","volume":"14","author":"Andrews N","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, et al.. Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England. Nat Med. 2022, 14:10.1038\/d41591-022-00013-3","journal-title":"Nat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115634-a-hitchhikers-guide-to-worldwide-covid-19-vaccinations-a-detailed-review-of-monovalent-and-bivalent-vaccine-schedules-covid-19-vaccine-side-effects-and-effectiveness-against-omicron-and-delta-variants","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:16Z","timestamp":1707507676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115634-a-hitchhikers-guide-to-worldwide-covid-19-vaccinations-a-detailed-review-of-monovalent-and-bivalent-vaccine-schedules-covid-19-vaccine-side-effects-and-effectiveness-against-omicron-and-delta-variants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,2]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.29837","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,2]]}}}